Cell-based therapy for idiopathic pulmonary fibrosis

Area of Science:

• Pulmonology
• Regenerative Medicine
• Cell Biology

Background:

• Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease causing respiratory failure.
• Current treatments offer limited efficacy, highlighting the need for novel therapeutic strategies.
• Stem cell therapy presents a promising avenue for treating IPF.

Purpose of the Study:

• To review recent advances in understanding IPF pathophysiology.
• To summarize the types of cells investigated for IPF cell-based therapies.
• To discuss the application, delivery, dosage, and timing of stem cell therapy in IPF.

Main Methods:

• Literature review of recent advances in IPF pathophysiology.
• Analysis of studies on various cell types for IPF therapy, including stem cells.
• Examination of clinical trials investigating cell-based therapies for IPF.

Main Results:

• Significant progress in understanding IPF pathogenesis and identifying potential cell therapies.
• Various cell types, including mesenchymal stem cells (MSCs), adipose-derived stem cells (ADSCs), and induced pluripotent stem cells (iPSCs), show therapeutic potential.
• Ongoing clinical trials are evaluating the safety and efficacy of cell-based treatments for IPF.

Conclusions:

• Cell-based therapies, particularly those using stem cells, offer a promising future for IPF treatment.
• Further research into optimal cell types, delivery methods, and clinical application is crucial.
• Translational research is actively progressing from preclinical studies to patient care worldwide.